Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24753435 | 0.92 | ALDH1A1 (0.52) | ALDH1A1ESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL30120162 | 0.92 | ALDH1A1 (0.52) | ALDH1A1ESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL29580471 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PDGFRBPDGFRAMEN1KMT2A | |
| SCHEMBL14582923 | 0.79 | ESR2 (0.48) | ALDH1A1ESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL346120 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PDGFRBPDGFRAMEN1KMT2A | |
| SCHEMBL1441691 | 0.78 | ESR2 (0.49) | ALDH1A1ESR2PDGFRBPDGFRAMEN1 | |
| Ammonia Solution, Strong SCHEMBL28148393 | 0.78 | ALDH1A1 (0.53) | ALDH1A1PDGFRBPDGFRAMEN1KMT2A | |
| SCHEMBL4540262 | 0.76 | ALDH1A1 (0.52) | ALDH1A1NPC1 | |
| SCHEMBL780275 | 0.76 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL1258593 | 0.76 | ALDH1A1 (0.52) | ALDH1A1PDGFRBPDGFRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101941947-A | Synthesis method of 2-chloro-6-chloroquinoxaline | SHAN DONG CHAMBROAD HOLDING CO LTD | 2011-01-12 | — | — | CN | claimed |
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-20140088306-A1 | RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2711026-A1 | Radioactive fluorine-labeled quinoxaline compound | Kyoto University (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7951955-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-05-31 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
| WO-1991001977-A1 | PROCESS FOR PREPARING 2,6-DICHOLOROQUINOXALINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2053/4885ESR2 4226/4885PDGFRB 3090/4885 |
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 2469/4885ESR2 4498/4885PDGFRB 3645/4885 |
| US-20140088306-A1 | RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND | APP, PSEN1, APBA1 | ALDH1A1 4371/4885ESR2 2987/4885PDGFRB 3916/4885 |
| US-20130005736-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 2469/4885ESR2 4498/4885PDGFRB 3645/4885 |
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 2469/4885ESR2 4498/4885PDGFRB 3645/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | ALDH1A1 859/4885ESR2 3767/4885PDGFRB 2406/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 2469/4885ESR2 4498/4885PDGFRB 3645/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | ALDH1A1 1576/4885ESR2 4450/4885PDGFRB 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.